Because HBV-related HCC usually has higher VEGF expression, it can be more responsive to VEGF-targeted TKIs [41], resulting in a better response and greater survival benefits in patients with HBV infection who receive the combination of TACE and TKIs. Here, VEGFA is linked to hepatocellular carcinoma.